A National Bioeconomy Manufacturing and Innovation Initiative
Summary
The COVID-19 pandemic has devastated the world. In the same year, record fires, hurricanes, and weather wreaked havoc on the United States. These disasters have had devastating economic effects on American lives. To combat COVID-19, foster economic recovery, and address climate change, the United States should implement a National Bioeconomy Manufacturing and Innovation Initiative. The U.S. bioeconomy is composed of healthcare, agriculture, and life-science companies and contributes an estimated 2% of the U.S. GDP. This figure is expected to rise in the coming decade. The bioeconomy also contributes to addressing climate change by reducing U.S. dependence on petroleum-based products and creates American jobs through a growing biomanufacturing sector. Biomanufacturing is the production of products via biological and biosynthetic mechanisms, such as fermentation-based production of industrial ethanol. To fully realize the potential of the bioeconomy, the United States must invest in cross-cutting research and development (R&D) across the areas of healthcare, food & agriculture, energy, environment, and industrial applications. The pillars of this “National Bioeconomy Manufacturing and Innovation Initiative” should focus on (1) cutting-edge R&D, (2) development of fundamental and publicly available tools, and (3) biomanufacturing. The initiative should be coordinated out of the Executive Office of the President via a National Bioeconomy Coordination Office. The initiative should be supported by senior leadership positions at each federal agency with equities in the U.S. bioeconomy, as well as by appropriated funding.
Good information sources, like collections, must be available and maintained if companies are going to successfully implement the vision of AI for science expressed by their marketing and executives.
Nestled in the cuts and investments of interest to the S&T community is a more complex story of how the administration is approaching the practice of science diplomacy.
By structuring licensing-and-talent deals that replicate mergers while avoiding antitrust scrutiny, dominant technology firms are reshaping AI labor markets, venture financing, and the future of U.S. innovation.
It is in the interests of the United States to appropriately protect information that needs to be protected while maintaining our participation in new discoveries to maintain our competitive advantage.